CN1931245B - 一种治疗痛风性关节炎的药物及其加工方法和应用 - Google Patents
一种治疗痛风性关节炎的药物及其加工方法和应用 Download PDFInfo
- Publication number
- CN1931245B CN1931245B CN200610037537A CN200610037537A CN1931245B CN 1931245 B CN1931245 B CN 1931245B CN 200610037537 A CN200610037537 A CN 200610037537A CN 200610037537 A CN200610037537 A CN 200610037537A CN 1931245 B CN1931245 B CN 1931245B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- gouty arthritis
- treatment
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 201000005569 Gout Diseases 0.000 title claims abstract description 57
- 206010018634 Gouty Arthritis Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title description 14
- 239000002775 capsule Substances 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 12
- 239000007924 injection Substances 0.000 claims abstract description 12
- 239000003826 tablet Substances 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 28
- 239000003960 organic solvent Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000003672 processing method Methods 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 6
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 6
- 239000007927 intramuscular injection Substances 0.000 claims description 6
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 229940090181 propyl acetate Drugs 0.000 claims description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 241000735234 Ligustrum Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 14
- 230000036407 pain Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 229960001338 colchicine Drugs 0.000 description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- -1 acetone Chemical class 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003270 steroid hormone Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000022371 chronic pain syndrome Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000065 osmolyte Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 241000580923 Acer buergerianum Species 0.000 description 1
- 235000001250 Cardamine diphylla Nutrition 0.000 description 1
- 244000250392 Cardamine diphylla Species 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 201000001819 hydrarthrosis Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610037537A CN1931245B (zh) | 2006-09-06 | 2006-09-06 | 一种治疗痛风性关节炎的药物及其加工方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610037537A CN1931245B (zh) | 2006-09-06 | 2006-09-06 | 一种治疗痛风性关节炎的药物及其加工方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1931245A CN1931245A (zh) | 2007-03-21 |
CN1931245B true CN1931245B (zh) | 2010-05-26 |
Family
ID=37877367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610037537A Active CN1931245B (zh) | 2006-09-06 | 2006-09-06 | 一种治疗痛风性关节炎的药物及其加工方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1931245B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104644768A (zh) * | 2015-02-07 | 2015-05-27 | 广州暨南生物医药研究开发基地有限公司 | 一种中药组合物在制备治疗肾脏疾病药物中的用途 |
CN104644769A (zh) * | 2015-02-07 | 2015-05-27 | 广州暨南生物医药研究开发基地有限公司 | 一种中药组合物在制备治疗前列腺炎药物中的用途 |
CN104644770A (zh) * | 2015-02-07 | 2015-05-27 | 广州暨南生物医药研究开发基地有限公司 | 一种中药组合物在制备治疗代谢类疾病药物中的用途 |
CN104800298B (zh) * | 2015-03-25 | 2017-10-31 | 广东大鹏医药科技有限公司 | 一种用于治疗痛风的中药颗粒制剂及其制备方法 |
CN104825554B (zh) * | 2015-04-22 | 2017-12-29 | 广东大鹏医药科技有限公司 | 一种治疗痛风性关节炎的喷雾剂 |
CN108371676B (zh) * | 2018-05-18 | 2021-06-29 | 广州暨南生物医药研究开发基地有限公司 | 一种虎贞痛风超微粉的制备方法 |
CN108524612B (zh) * | 2018-07-03 | 2021-04-20 | 广州暨南生物医药研究开发基地有限公司 | 一种虎贞痛风纳米颗粒剂的制备方法 |
CN111419945A (zh) * | 2020-04-26 | 2020-07-17 | 广东大鹏医药科技有限公司 | 一种虎贞痛风片剂及其制备方法与应用 |
CN116421650B (zh) * | 2023-05-08 | 2023-12-08 | 上饶智江信息科技有限公司 | 一种用于治疗急性痛风性关节炎的胶囊及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371726A (zh) * | 2002-03-20 | 2002-10-02 | 黄资源 | 一种治疗乙型肝炎实证的乙肝化毒煎丸剂 |
-
2006
- 2006-09-06 CN CN200610037537A patent/CN1931245B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371726A (zh) * | 2002-03-20 | 2002-10-02 | 黄资源 | 一种治疗乙型肝炎实证的乙肝化毒煎丸剂 |
Non-Patent Citations (4)
Title |
---|
乐枫 |
乐枫;钱耀明;顾宝妹.急痛汤治疗急性痛风110例疗效观察.河北中医25 2.2003,25(2),108. * |
钱耀明 |
顾宝妹.急痛汤治疗急性痛风110例疗效观察.河北中医25 2.2003,25(2),108. |
Also Published As
Publication number | Publication date |
---|---|
CN1931245A (zh) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1931245B (zh) | 一种治疗痛风性关节炎的药物及其加工方法和应用 | |
CN102058673B (zh) | 一种祛风除湿的中药组合物及其制备方法 | |
CN100443112C (zh) | 一种治疗痛风及痛风性关节炎的药物 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN101757591B (zh) | 一种治疗慢性结肠炎、直肠炎的中药组合物 | |
CN102961508A (zh) | 一种用于治疗前列腺炎前列腺增生的中药组合物 | |
CN106581092A (zh) | 红柳提取物及其在制备治疗类风湿关节炎药物中的应用 | |
CN104825788A (zh) | 一种中药组合物在制备治疗短暂性脑缺血发作的药物中的应用 | |
CN102772712A (zh) | 一种治疗热毒炽盛血瘀型糖尿病足的中药组合物 | |
CN101342356B (zh) | 一种用于淤血阻滞、脉管不通的中药制剂及其制备方法 | |
CN104258051B (zh) | 一种治疗痛风性关节炎的中药组合物及其制备方法 | |
CN101584810A (zh) | 一种治疗胃炎、消化性溃疡的药物组合物及其制备方法 | |
CN103751450B (zh) | 一种治疗糖尿病肾病的组合物 | |
CN103830589B (zh) | 一种治疗高血压肾损害的药物组合物及制备方法和用途 | |
CN100333758C (zh) | 一种抗痛风中药的组合物及其制备方法 | |
CN102293928A (zh) | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 | |
CN103908600A (zh) | 治疗类风湿性关节炎湿热痹阻证的外用药物、制备方法及给药方式 | |
CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 | |
CN101732386A (zh) | 治疗痛风的药物组合物及其制备方法与用途 | |
CN103285360B (zh) | 一种治疗血栓闭塞性脉管炎的中药制剂及其制备方法 | |
CN106138494B (zh) | 一种养肾组合物及其生产方法 | |
CN108743885A (zh) | 一种治疗糖尿病大血管病变的中药及其制备方法 | |
CN115192657B (zh) | 一种用于治疗2型糖尿病肾脏病的中药制剂及其应用 | |
CN103316226B (zh) | 一种治疗冠心病的中药组合物 | |
CN102335304B (zh) | 一种祛风燥湿活血止痛的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yifei Inventor after: Li Jiuxiang Inventor after: Wang Zhiping Inventor after: Yang Ke Inventor before: Li Jiuxiang Inventor before: Wang Yifei Inventor before: Wang Zhiping Inventor before: Yang Ke |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240305 Address after: 526200 Fengshan Road, Dongcheng District, Sihui City, Zhaoqing City, Guangdong Province Patentee after: Yili Pharmaceutical Co.,Ltd. Country or region after: China Address before: 510632 No. 601, Whampoa Avenue, Tianhe District, Guangdong, Guangzhou Patentee before: Jinan University Country or region before: China |
|
TR01 | Transfer of patent right |